Article
SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells.
Leukemia - 1 Dec 2018
Liang Yang, Tebaldi Toma, Rejeski Kai, Joshi Poorval, Stefani Giovanni, Taylor Ashley, Song Yuanbin, Vasic Radovan, Maziarz Jamie, Balasubramanian Kunthavai, Ardasheva Anastasia, Ding Alicia, Quattrone Alessandro, Halene Stephanie
Abstract excerpt
Recurrent mutations in the splicing factor SRSF2 are associated with poor clinical outcomes in myelodysplastic syndromes (MDS). Their high frequency suggests these mutations drive oncogenesis, yet the molecular explanation for this process is unclear. SRSF2 mutations could directly affect pre-mRNA splicing of a vital gene product; alternatively, a whole network of gene products could be affected. Here we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.